

Market Announcement

3 March 2025

Chimeric Therapeutics Limited (ASX: CHM) – Suspension from Quotation

Description

The securities of Chimeric Therapeutics Limited ('CHM') will be suspended from quotation immediately under Listing Rule 17.2, at the request of CHM, pending the release of an announcement regarding a capital raising.

Issued by

ASX Compliance



3 March 2025

Lisa Banh
Senior Adviser, Listings Compliance
ASX Compliance Pty Ltd
20 Bridge Street
Sydney NSW 2000

Via email

Dear Lisa

Chimeric Therapeutics Limited (ASX: CHM)

Request for Voluntary Suspension

Further to the trading halt requested and granted on 27 February 2025, and in accordance with ASX Listing Rule 17.2, Chimeric Therapeutics Limited (ASX: CHM) (the **Company**) requests voluntary suspension of its securities effective immediately pending an announcement by the Company in relation to a capital raising, which the Company anticipates will be made prior to commencement of trading on Tuesday, 4 March 2025.

The trading halt was requested in relation to a capital raising and non-dilutionary funding. The timing of the capital raising was impacted by the limited availability of potential investors during the reporting season.

The Company is not aware of any reason why its securities should not be suspended.

There is no other information necessary to inform the market about the suspension.

Please contact me if you require any further information.

Yours sincerely

Phillip Hains
Joint Company Secretary